It is the operating environment around it: the data foundation, the governance, and the way sponsors and CDMOs coordinate. BAMI is a framework for diagnosing that environment.
Introduced by Axio BioPharma in its 2026 report AI in Biomanufacturing, BAMI outlines a structured approach for evaluating whether AI systems can realistically move beyond isolated pilots into governed, repeatable, and scalable operational deployment.
The ability to integrate and contextualize data across manufacturing and enterprise systems.
Ownership, monitoring, validation, change control, and inspection readiness for AI-enabled systems.
The ability to transfer models, process knowledge, and operational intelligence across sites and partners.
Alignment across MES, LIMS, historians, analytics layers, and decision workflows.
Preparedness for evolving expectations around AI-enabled systems in GxP environments.
BAMI reflects the operational realities of modern biomanufacturing, where execution increasingly spans sponsors, CDMOs, digital systems, and external partners.
Rather than positioning AI as a standalone capability, the framework considers whether the surrounding operating environment can support scalable and governed AI deployment across sites, organizations, and regulated workflows.
It also aligns conceptually with broader industry maturity initiatives such as DPMM and DISCO, helping organizations connect digital maturity with practical AI capability and deployment readiness.
Axio BioPharma is building an interactive self-assessment based on the BAMI framework, a structured way to evaluate AI readiness, identify operational and governance gaps, and understand what it takes to support scalable AI-enabled manufacturing.
